LC/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 4, 2010, Pages 824-833

  Wang, Jennie ^a   Krishnamoorthi, Vidhya ^a   Wang, Euphemia ^a   Yang, Chun ^a   Baptista, Diego ^a   Wu, Xiaogang ^a   Liu, Mingtao ^a   Gardner, Michael ^b   Elkins, Phyllis ^b   Hines, John ^b   Liu, Paul ^c  

^a SRI INTERNATIONAL   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B201; Bradykinin antagonist; CU201; Impurities characterization; LC MS; Peptidic dimer

Indexed keywords

ANTINEOPLASTIC AGENT; CU 201; NSC 734868; SUBERIMIDYL [DEXTRO ARGINYLARGINYLPROLYL 4 HYDROXYPROLYLGLYCYL ALPHA (2 INDANYL)GLYCYLSERYL DEXTRO ALPHA (2 INDANYL)GLYCYL OCTAHYDROINDOLE 2 CARBOXYLIC ACID ARGININE]; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG IMPURITY; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DRUG CONTAMINATION; DRUG STABILITY; HYDROLYSIS; MASS SPECTROMETRY; OLIGOPEPTIDES; PROTEIN MULTIMERIZATION;

EID: 72149115643     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.10.004     Document Type: Article

References (13)

1. Gera L., Stewart J.M., Whalley E., Burkard M., and Zuzack J.S. Immunopharmacology 33 (1996) 178-182
2. Chan D., Gera L., Stewart J., Hekfrich B., Verella-Garcia M., Johnson G., Baron A., Yang J., Puck T., and Bunn Jr. P. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 4608-4613
3. Stewart J.M., Gera L., Chan D.C., Bunn Jr. P.A., York E.J., Simkeviciene V., and Helfrich B. Can. J. Physiol. Pharmacol. 80 (2002) 275-280
4. Morssette G., Houle S., Gera L., Stewart J.M., and Marceau F. Br. J. Pharmacol. 150 (2007) 369-379
5. Stewart J.M., Gera L., Chan D.C., York E.J., Simkeviciene V., Bunn Jr. P.A., and Taraseviciene-Stewart L. Peptides 26 (2005) 1288-1291
6. Chan D.C., Gera L., Stewart J.M., Helfrich B., Zhao T.L., Feng W.Y., Chan K.K., Covey J.M., and Bunn Jr. P. Clin. Cancer Res. 8 (2002) 1280-1287
7. Thomas S.M., Bhola N.E., Zhang Q., Contrucci S.C., Wentzel A.L., Freilino M.L., Gooding W.E., Siegfried J.M., Chan D.C., and Grandis J.R. Cancer Res. 66 (2006) 11831-11839
8. Feng W.Y., Chan K.K., and Covey J.M. J. Pharm. Biomed. Anal. 28 (2002) 601-612
9. L.R. Snyder, J.J. Kirkland, J.L. Glajch, Practical HPLC Method Development, 2nd ed., John Wiley & Sons, Inc., 1997, pp. 497-509.
10. Watson E., and Kenney W.C. J. Chromatogr. 606 (1993) 165-170
11. Melander W., Lin H.J., Jacobsson J., and Horvath C. J. Phys. Chem. 88 (1984) 4527-4536
12. Russell D.H., and Edmondson R.D. J. Mass Spectrom. 32 (1997) 263-276
13. Tahara S., Shigetsuna M., and Otomasu H. Chem. Pharm. Bull. 30 (1982) 3133-3138